Sotorasib — Drug Intelligence | 16 EU Trials

Filter these 16 trials by condition, phase, country and more.

Open in Search →

16 Registered trials

5 Recruiting

10 Completed trials

11 Sponsors

21 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 4 Phase II: 6 Phase I/II: 2 Phase IV: 1 Phase I (Other): 1 Phase I (FiH): 2

Indications tested

Non-small cell lung cancer 6 Colorectal adenocarcinoma 1 Non-small cell lung cancer stage IV 1 Non-small cell lung cancer stage III 1 Colorectal cancer 1

Sponsors using this IMP

Amgen Inc. 6 Asociacion Grupo Tratamiento De Tumores Digestivos 1 Deciphera Pharmaceuticals Inc. 1 Fondation Franc.Cancerologie Digestive 1 Fondazione GONO G.I. 1 Fundacion GECP 1 Institut Gustave Roussy 1 Orion Corporation 1 Stichting Radboud University Medical Center 1 Verastem Inc. 1 Vestre Viken HF 1

All trials

16 total

Trial to study the safety and pharmacokinetics of ODM-212 combined with existing cancer treatments Pending

2025-524620-22-00 Phase I/II 4 countries Orion Corporation
Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma Recruiting

2024-516233-12-00 Phase I (Other) 2 countries Asociacion Grupo Tratamiento De Tumores Digestivos
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 Phase II 4 countries Fondation Franc.Cancerologie Digestive
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Phase III 18 countries Amgen Inc.
Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and re… Recruiting

2022-501308-90-00 Phase II 1 country Fondazione GONO G.I.
Sotorasib in advanced KRAS G12C-mutated non-small cell lung cancer patients with comorbidities (SOLUCOM) Recruiting

2023-503174-20-00 Phase II 3 countries Vestre Viken HF
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib in G12C NSCLC Patients (RAMP203) Ended

2023-505107-24-00 Phase I/II 4 countries Verastem Inc.
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Phase III 17 countries Amgen Inc.
An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With M… Ended

2024-510837-16-00 Phase II 1 country Institut Gustave Roussy
A research study to evaluate the activity of Sotorasib for the treatment of patients with non-operable non-small cell lung cancer with a KRA… Ended

2024-511268-10-00 Phase II 1 country Fundacion GECP
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200) Ended

2023-508214-42-00 Phase III 8 countries Amgen Inc.
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specifi… Ended

2024-511798-31-00 Phase I (FiH) 8 countries Amgen Inc.
Rivaroxaban sotorasib interaction study Ended

2023-505557-41-00 Phase IV 1 country Stichting Radboud University Medical Center
Sotorasib and Panitumumab Versus Investigator’s Choice for Subjects with KRAS p.G12C Mutation (CodeBreaK 300) Ended

2024-511187-81-00 Phase III 5 countries Amgen Inc.
Sotorasib (AMG 510) in Subjects with NSCLC with KRASG12C Mutation in Need of First-Line Treatment Ended

2024-511189-36-00 Phase II 5 countries Amgen Inc.
A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Ended

2022-501474-19-00 Phase I (FiH) 4 countries Deciphera Pharmaceuticals Inc.

Showing 1–16 of 16 trials

← All drugs A–Z